Adherium Ltd. AI Stock Analysis
Want to see AU:ADR full AI Analyst Report?
Adherium Ltd. (ADR) AI Stock Analysis
Adherium Ltd.
(ASX:ADR)
Overall score reflects a high-risk profile driven primarily by weak financial performance (large ongoing losses, sustained cash burn, and negative equity). Technicals further weigh on the score given bearish momentum and trading below key moving averages, while valuation is difficult to justify on earnings due to a negative P/E and no provided dividend yield.
Adherium Ltd. (ADR) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 963.42K
- Dividend Yield
- ―
- Average Volume (3M)
- 47.42K
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- 1.18
- Revenue Growth
- 157.02%
- EPS Growth
- 69.43%
- Country
- Australia
- Employees
- 40
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Adherium Ltd. Business Overview & Revenue Model
Company Description
Adherium Limited specializes in developing, manufacturing, and providing advanced digital health solutions. The company's core mission is to enhance medication adherence for individuals managing chronic conditions in key international markets, spanni...
Adherium Ltd. Financial Statement Overview
Summary
Financial statements indicate high risk: despite an ~88% revenue rebound in 2026 and improved gross margin (~58%), the company remains deeply unprofitable with operating and net losses far exceeding revenue, persistent negative operating/free cash flow (large 2026 outflow), and negative shareholder equity in 2025–2026, which raises solvency and financing-dependence concerns.
Income Statement
18Very NegativeBalance Sheet
22NegativeCash Flow
15Very Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.10M | 2.10M | 817.24K | 840.98K | 3.19M | 529.00K |
| Gross Profit | 1.22M | 1.22M | 111.37K | 267.70K | 1.69M | -690.00K |
| EBITDA | -14.36M | -14.36M | -12.44M | -11.56M | -11.50M | -12.65M |
| Net Income | -14.16M | -14.16M | -12.68M | -10.22M | -9.86M | -10.04M |
Balance Sheet | ||||||
| Total Assets | 4.56M | 4.56M | 3.52M | 9.89M | 12.68M | 8.53M |
| Cash, Cash Equivalents and Short-Term Investments | 1.42M | 1.42M | 43.26K | 6.20M | 9.08M | 5.28M |
| Total Debt | 2.40M | 2.40M | 3.12M | 93.20K | 44.00K | 85.00K |
| Total Liabilities | 5.85M | 5.85M | 8.28M | 3.41M | 3.47M | 3.00M |
| Stockholders Equity | -1.29M | -1.29M | -4.76M | 6.48M | 9.21M | 5.54M |
Cash Flow | ||||||
| Free Cash Flow | -14.87M | -14.87M | -10.03M | -10.61M | -9.32M | -9.89M |
| Operating Cash Flow | -14.83M | -14.83M | -9.98M | -10.61M | -9.28M | -9.61M |
| Investing Cash Flow | -39.00K | -39.00K | -48.19K | -37 | -41.00K | -279.00K |
| Financing Cash Flow | 16.32M | 16.32M | 3.87M | 7.73M | 13.07M | 0 |
Adherium Ltd. Peers Comparison
Overall Rating
AU:ALC63Neutral
AU:AHE44Neutral
AU:BMT40Underperform
AU:ICR40Underperform- AU:ADR40Underperform
AU:PCK38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:ALC | 63Neutral | AUD 141.73M | 65.88 | 2.53% | ― | 26.61% | 41.67% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:AHE | 44Neutral | AUD 8.29M | -0.42 | -614.15% | ― | -46.09% | 70.70% |
| AU:BMT | 40Underperform | AUD 21.26M | -1.14 | -58.13% | ― | 2.08% | -195.31% |
| AU:ICR | 40Underperform | AUD 12.88M | -5.00 | -416.53% | ― | 113.42% | 29.17% |
| AU:ADR | 40Underperform | AUD 2.85M | -0.13 | 1363.47% | ― | 157.02% | 69.43% |
| AU:PCK | 38Underperform | AUD 14.65M | -1.59 | -1688.04% | ― | 11.45% | 0.69% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:ADR | Adherium Ltd. | 0.05 | -0.14 | -72.63% | |
| AU:BMT | Beamtree Holdings Ltd | 0.07 | -0.13 | -64.00% | |
| AU:AHE | MedAdvisor Limited | 0.01 | -0.01 | -45.83% | |
| AU:ALC | Alcidion Group Limited | 0.12 | 0.01 | 15.00% | |
| AU:ICR | InteliCare Holdings Limited | 0.02 | -0.01 | -29.17% | |
| AU:PCK | PainChek Ltd | 0.07 | -0.38 | -83.78% |
Adherium Ltd. Corporate Events
Adherium Secures Additional Funding from Barvest to Support Working Capital
Adherium Limited, a Melbourne-based digital health company, specialises in connected respiratory medical devices and the FDA-cleared Hailie Smartinhaler platform, which enables remote monitoring of medication use and adherence for patients with respi...
Adherium Sets 2026 AGM, Seeks Extra Placement Capacity and Board Changes
Adherium Limited has called its 2026 Annual General Meeting for 30 November, to be held virtually, with shareholders able to vote and submit questions online or by proxy under updated electronic communication rules. The meeting will consider the adop...
Adherium Expands U.S. Footprint With Florida Pulmonary Group Hailie Deal
Adherium has entered a partnership with Florida Lung, Asthma & Sleep Specialists, an independent pulmonary and critical care practice in Central Florida, to deploy its Hailie Smartinhaler platform across the group’s greater Orlando locations. The rol...
Adherium Secures Non-Dilutive AUD$700,000 Loan to Support Working Capital
Adherium Limited, a global provider of connected respiratory medical devices and digital health solutions, has built its Hailie platform to support remote monitoring of respiratory medication use. The system integrates sensors, mobile and desktop app...
Adherium Lodges Updated Corporate Governance Statement with ASX
Adherium Ltd has lodged its corporate governance statement for the year ended 30 June 2026 with the ASX, confirming that the document is current as at 30 September 2026 and is available via the company’s investor website. The filing, accompanied by a...
Adherium Secures A$4.67m Term Loan from Major Shareholder Trudell
Adherium Limited, a global player in digital respiratory management and connected inhaler technology, has consolidated its recent funding arrangements from major shareholder Trudell Medical into a single unsecured term loan. The company’s solutions,...
Adherium Boosts U.S. Revenue but Loss Widens on Growth Investments
Adherium reported a 157% jump in revenue to $2.1 million for the year to 30 June 2026, driven by the successful launch of its remote patient monitoring program in the United States. Despite the revenue surge, the company’s net loss widened to $14.2 m...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 24, 2026